Abbvie Inc

NYSE: ABBV
$193.46
-$0.16 (-0.1%)
Closing Price on September 20, 2024

ABBV Articles

The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Apple, Broadcom, Exxon Mobil, Fabrinet, HP, Match and Target.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
AbbVie is trying one of the older and less-used efforts to drive its share price back up: a modified Dutch tender auction.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
Monday was an incredible day for the broad U.S. markets, with the Dow posting one of its top 3 performances, in terms of points, in the history of the average. The S&P 500 and Nasdaq had...
AbbVie shares took a big step back last week after the firm reported less than favorable results for its relapsed/refractory small cell lung cancer trial.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, American Water, Carnival, Cisco, Darden, DexCom, Micron Technology, Nike and Occidental Petroleum.
Thursday was an absolute disaster for the broad U.S. markets. There didn’t seem to be anything positive about Thursday for any of the major indices. The Dow was the biggest loser of the group, it...
AbbVie saw its shares pull back on Thursday after it reported less than favorable midstage results for its relapsed/refractory small cell lung cancer trial.
Jefferies has made a big move by adding a top retail company to its well-respected Franchise Picks list of stocks to Buy.